Lysophosphatidic acid is a bioactive mediator in ovarian cancer

Xianjun Fang; Michel Schummer; Muling Mao; Shuangxing Yu; Fazal Haq Tabassam; Ramona Swaby; Yutaka Hasegawa; Janos L. Tanyi; Ruthie LaPushin; Astrid Eder; Robert Jaffe; Jim Erickson; Gordon B. Mills

doi:10.1016/S1388-1981(02)00179-8

Lysophosphatidic acid is a bioactive mediator in ovarian cancer

Xianjun Fang, Michel Schummer, Muling Mao, Shuangxing Yu, Fazal Haq Tabassam, Ramona Swaby, Yutaka Hasegawa, Janos L. Tanyi, Ruthie LaPushin, Astrid Eder, Robert Jaffe, Jim Erickson, Gordon B. Mills

Research output: Contribution to journal › Review article › peer-review

243 Scopus citations

Abstract

Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies.

Original language	English (US)
Pages (from-to)	257-264
Number of pages	8
Journal	Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Volume	1582
Issue number	1-3
DOIs	https://doi.org/10.1016/S1388-1981(02)00179-8
State	Published - May 23 2002
Externally published	Yes

Keywords

Cancer therapy
Cell survival
Edg receptor
Lysophosphatidic acid
Ovarian cancer

ASJC Scopus subject areas

Molecular Biology
Cell Biology

Access to Document

10.1016/S1388-1981(02)00179-8

Cite this

@article{f829c3584e79475681589f5d0da7e287,

title = "Lysophosphatidic acid is a bioactive mediator in ovarian cancer",

abstract = "Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies.",

keywords = "Cancer therapy, Cell survival, Edg receptor, Lysophosphatidic acid, Ovarian cancer",

author = "Xianjun Fang and Michel Schummer and Muling Mao and Shuangxing Yu and Tabassam, {Fazal Haq} and Ramona Swaby and Yutaka Hasegawa and Tanyi, {Janos L.} and Ruthie LaPushin and Astrid Eder and Robert Jaffe and Jim Erickson and Mills, {Gordon B.}",

note = "Funding Information: The work has been supported by the NIH grants CA82716 and CA64602 to G.B.M., and by the Lynne Cohen Foundation Ovarian Cancer Research fund 80095031 to X.F. M.S. was supported by the Marsha Rivkin Center for Ovarian Cancer Research, Seattle, WA.",

year = "2002",

month = may,

day = "23",

doi = "10.1016/S1388-1981(02)00179-8",

language = "English (US)",

volume = "1582",

pages = "257--264",

journal = "Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids",

issn = "1388-1981",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Lysophosphatidic acid is a bioactive mediator in ovarian cancer

AU - Fang, Xianjun

AU - Schummer, Michel

AU - Mao, Muling

AU - Yu, Shuangxing

AU - Tabassam, Fazal Haq

AU - Swaby, Ramona

AU - Hasegawa, Yutaka

AU - Tanyi, Janos L.

AU - LaPushin, Ruthie

AU - Eder, Astrid

AU - Jaffe, Robert

AU - Erickson, Jim

AU - Mills, Gordon B.

N1 - Funding Information: The work has been supported by the NIH grants CA82716 and CA64602 to G.B.M., and by the Lynne Cohen Foundation Ovarian Cancer Research fund 80095031 to X.F. M.S. was supported by the Marsha Rivkin Center for Ovarian Cancer Research, Seattle, WA.

PY - 2002/5/23

Y1 - 2002/5/23

N2 - Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies.

AB - Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies.

KW - Cancer therapy

KW - Cell survival

KW - Edg receptor

KW - Lysophosphatidic acid

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0242339246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242339246&partnerID=8YFLogxK

U2 - 10.1016/S1388-1981(02)00179-8

DO - 10.1016/S1388-1981(02)00179-8

M3 - Review article

C2 - 12069836

AN - SCOPUS:0242339246

SN - 1388-1981

VL - 1582

SP - 257

EP - 264

JO - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

JF - Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

IS - 1-3

ER -

Lysophosphatidic acid is a bioactive mediator in ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this